Respiratory Illness Questionnaire-Monitoring 10

1. Abstract

The Respiratory Illness Questionnaire-Monitoring 10 (commonly abbreviated as the RIQ-MON10 or Riq-mon10) is a standardized, patient-reported outcome measure (PROM) designed to assess health-related quality of life (HRQoL) and disease burden in individuals diagnosed with obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD) and bronchial asthma. Originating as an abbreviated, psychometrically optimized derivative of the comprehensive 55-item Quality of Life for Respiratory Illness Questionnaire (QoL-RIQ) formulated by Albert R. Maille and colleagues in 1997, the RIQ-MON10 addresses the critical clinical need for an ultra-brief, psychometrically robust monitoring tool suitable for routine longitudinal administration in both outpatient primary care and specialized pulmonary rehabilitation contexts.

The scale consists of 10 items structured across two core higher-order domains: (1) Physical and Emotional Complaints, which captures the immediate somatic intrusion of dyspnea, fatigue, respiratory distress, and associated psychological vulnerability (e.g., anxiety and emotional frustration); and (2) Physical and Social Limitations, which quantifies functional performance restrictions, interference with daily domestic activities, and impaired social engagement. Items are typically scored on an ordinal Likert-type scale reflecting symptom frequency or perceived impairment over a defined recall period (typically the past 1 to 2 weeks). Extensive psychometric evaluations indicate that the RIQ-MON10 preserves the structural integrity of its parent instrument while significantly minimizing respondent burden. Internal consistency reliability coefficients (Cronbach’s alpha) typically range between .78 and .88 across the subscales and total score, with high test-retest reliability (intraclass correlation coefficients exceeding .80) observed in clinically stable patient cohorts. Furthermore, the questionnaire demonstrates strong convergent validity with physiological indices (such as forced expiratory volume in one second; FEV₁), generic quality of life indices (e.g., the SF-36), and legacy respiratory instruments like the St. George’s Respiratory Questionnaire (SGRQ), rendering it an exceptional clinical epidemiology instrument for tracking therapeutic trajectories and pulmonary outcomes.

2. Keywords

Respiratory Illness Questionnaire-Monitoring 10, RIQ-MON10, Chronic Obstructive Pulmonary Disease, COPD, Asthma, Health-Related Quality of Life, Patient-Reported Outcome Measures, Psychometrics, Pulmonary Rehabilitation, Dyspnea Burden

3. Authors

The original conceptualization, psychometric reduction, and empirical validation of the Respiratory Illness Questionnaire-Monitoring 10 were conducted by:

• Albert R. Maille, Ph.D. — Department of General Practice and Primary Care, Leiden University Medical Center (LUMC), Leiden, The Netherlands; and the Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands. Dr. Maille’s seminal work focused on behavioral medicine, respiratory disease management, and the development of multidimensional health status indices for chronic pulmonary conditions.
• Collaborating Research Group: Department of Pulmonology and the Asthma/COPD Primary Care Research Consortium, Leiden University, including contributions from methodological and clinical researchers specializing in respiratory epidemiology and psychometric validation (e.g., A. A. Kaptein, J. Hermans, and colleagues associated with the broader development and validation of the parent QoL-RIQ framework).

4. Purpose

Chronic respiratory disorders, principally chronic obstructive pulmonary disease (COPD) and chronic asthma, are progressive, systemic conditions characterized by persistent airflow limitation, acute exacerbations, systemic inflammation, and marked functional decline. While traditional clinical practice relies heavily on objective physiological parameters—such as spirometry, forced vital capacity (FVC), and forced expiratory volume in one second (FEV₁)—clinical evidence consistently demonstrates a distinct dissociation between physiological airway obstruction and the subjective experience of illness. Two patients exhibiting identical spirometric impairment may report drastically divergent functional capacities, psychological burdens, and overall qualities of life. Consequently, patient-reported outcome measures (PROMs) have emerged as an indispensable pillar of comprehensive respiratory assessment.

Although comprehensive respiratory-specific instruments such as the 55-item Quality of Life for Respiratory Illness Questionnaire (QoL-RIQ), the 76-item St. George’s Respiratory Questionnaire (SGRQ), and the Chronic Respiratory Questionnaire (CRQ) offer deep phenotypic characterizations of patient impairment, their substantial length, administrative complexity, and cognitive burden impose formidable barriers to routine implementation in high-volume outpatient clinics and primary care consultations. In real-world clinical practice, healthcare providers often lack the clinical time necessary to administer, score, and interpret 50-to-75-item inventories at every patient visit.

The Respiratory Illness Questionnaire-Monitoring 10 (RIQ-MON10) was explicitly developed to resolve this structural tension. Its primary objectives are:

• Rapid Longitudinal Monitoring: To provide a concise, 10-item instrument capable of being completed by patients in fewer than three minutes in clinic waiting areas or via digital tele-monitoring platforms prior to medical encounters.
• Tracking Clinical Trajectories: To reliably identify acute deteriorations in health status indicative of incipient disease exacerbations, enabling early pharmacotherapeutic adjustment or behavioral intervention.
• Evaluating Interventional Efficacy: To quantify clinically meaningful changes resulting from therapeutic interventions, including pulmonary rehabilitation programs, smoking cessation regimens, bronchodilator therapy, inhaled corticosteroid adjustments, and oxygen therapy.
• Holistic Patient-Centered Communication: To furnish primary care physicians, pulmonologists, respiratory nurses, and physical therapists with a dual-dimensional profile isolating somatic-emotional distress from daily physical and social restrictions, thereby facilitating personalized care management.

5. Psychological Construct

The construct assessed by the RIQ-MON10 is respiratory-specific health-related quality of life (HRQoL), defined as the multidimensional impact of chronic respiratory impairment on an individual’s physical, functional, emotional, and social well-being. Unlike generic HRQoL tools (such as the Medical Outcomes Study Short Form-36), disease-specific instruments measure the distinct, idiosyncratic manifestations through which pulmonary compromise impairs lived experience. In the RIQ-MON10, this overarching construct is operationalized into two inter-correlated yet conceptually distinct dimensions:

1. Physical and Emotional Complaints

This dimension evaluates the immediate experiential impact of somatic respiratory symptomatology alongside the downstream emotional and affective reactions directly evoked by these physical sensations. In respiratory pathology, physical sensations such as breathlessness (dyspnea), chronic productive cough, wheezing, and chest tightness do not operate as isolated physiological events; rather, they are inextricably linked with psychophysiological distress. The sudden sensation of air hunger reliably stimulates autonomic hyperarousal, evoking acute panic, anticipatory anxiety, helplessness, and demoralization.

Items within this subscale assess the frequency and severity of respiratory distress during typical waking hours, the experience of sudden breathlessness, nocturnal sleep disruption due to respiratory discomfort, and the subjective distress (irritability, anxiety, and depressive affect) triggered by the patient’s perceived loss of somatic control. For example, an item measuring this domain queries the degree to which feelings of panic, tension, or exhaustion accompany bouts of coughing or acute breathlessness, operationalizing the vicious cycle wherein dyspnea induces affective distress, which in turn elevates ventilatory demand and further exacerbates dyspnea.

2. Physical and Social Limitations

The second core dimension quantifies functional impairment and restriction across domains of everyday domestic functioning, mobility, leisure engagement, and interpersonal connectivity. Chronic respiratory illness invariably leads to functional decrescendo: as exertional breathlessness advances, patients consciously and unconsciously adopt avoidance behaviors, systematically pruning activities that require metabolic expenditure.

This dimension captures limitations in executing basic and instrumental activities of daily living (ADLs), such as walking up a flight of stairs, performing light household chores, bending, carrying groceries, or pacing during self-care routines. Concurrently, it captures the social erosion associated with chronic lung conditions: social withdrawal stemming from embarrassment over productive coughing or supplemental oxygen use, inability to maintain pace with family and peers during leisure activities, cancellation of social engagements, and progressive interpersonal isolation. By capturing both physical performance bottlenecks and the curtailment of social participation, this dimension captures the societal and contextual disability imposed by respiratory pathology.

6. Theoretical Framework

The architectural design and validation of the RIQ-MON10 are grounded in the convergence of two foundational theoretical paradigms: the Biopsychosocial Model of Illness (Engel, 1977) and the World Health Organization’s International Classification of Functioning, Disability and Health (WHO-ICF framework).

The Biopsychosocial Paradigm

George Engel’s biopsychosocial framework posits that disease states cannot be fully comprehended or effectively managed through reductionist biomedical markers alone. In respiratory medicine, while cellular pathology (bronchial inflammation, alveolar destruction, loss of elastic recoil) dictates biological derangements, the clinical manifestations of illness are heavily mediated by cognitive appraisals, psychological resilience, affective states, and social support systems. The RIQ-MON10 reflects this integrative paradigm by treating biological impairment (dyspnea, cough), psychological distress (fear of suffocation, frustration), and social role disruption not as independent phenomena, but as interconnected components of a unified disease phenotype.

The ICF Disablement Model

The ICF framework distinguishes systematically between three levels of health experience: (1) Impairments in body functions or structures; (2) Activity Limitations encountered by an individual in executing tasks; and (3) Participation Restrictions experienced in societal involvement. The parent QoL-RIQ and the derivative RIQ-MON10 map directly onto this continuum:

• Impairment Level: Captured through items evaluating physical complaints (airway limitation, coughing, sleep disruption).
• Activity Limitation Level: Measured by items evaluating mobility, domestic task execution, and self-pacing deficits.
• Participation Restriction Level: Evaluated through items measuring disruption of family roles, withdrawal from community/social hobbies, and interpersonal strain.

The Cognitive-Behavioral Cycle of Dyspnea

Theoretical formulations by respiratory behavioral scientists (such as Kaptein, Maille, and colleagues) highlight the recursive cognitive-behavioral loop characteristic of chronic lung disease. Dyspnea elicits catastrophic cognitive interpretations (“I am suffocating”), generating sympathetic nervous system activation, hyperventilation, and dynamic hyperinflation. Over time, to avoid these distressing sensations, patients engage in systematic behavioral avoidance of exertional activities. This avoidance produces rapid skeletal muscle deconditioning, lowering the physiological threshold at which dyspnea occurs during subsequent physical exertion. The RIQ-MON10 explicitly samples items reflecting this dual dynamic—capturing both the experiential distress of symptoms and the resultant behavioral avoidance across domestic and social spheres.

7. Validity

The psychometric validity of the RIQ-MON10 has been demonstrated through multiple validation studies across both clinical trial settings and real-world primary care registries in Western Europe, particularly in the Netherlands.

Construct and Convergent Validity

Convergent validity has been established by correlating RIQ-MON10 domain and summary scores with established generic and pulmonary-specific outcome metrics:

• Generic HRQoL Measures: RIQ-MON10 total and subscale scores exhibit robust, statistically significant correlations with the Medical Outcomes Study Short Form-36 (SF-36). The Physical and Social Limitations dimension correlates strongly with the SF-36 Physical Functioning (r = -.62 to -.74) and Social Functioning (r = -.55 to -.68) subscales. The Physical and Emotional Complaints dimension demonstrates substantial convergence with the SF-36 Bodily Pain, Vitality, and Mental Health scales (r = -.50 to -.65).
• Respiratory-Specific Instruments: High convergent validity is documented against the parent 55-item QoL-RIQ, with bivariate correlation coefficients consistently exceeding r = .85 to .92, indicating that the 10-item short form successfully retains the fundamental measurement properties of the parent instrument. Strong correlations are likewise observed with the St. George’s Respiratory Questionnaire (SGRQ Total Score: r = .68 to .79) and the Clinical COPD Questionnaire (CCQ: r = .70 to .82).

Criterion and Physiological Validity

The relationship between RIQ-MON10 scores and physiological markers of respiratory compromise adheres closely to expectations established in pulmonary outcome literature:

• Correlations with spirometric indices (FEV₁ % predicted) are moderate (ranging from r = -.30 to -.45). This moderate association conforms to the well-documented “spirometry-HRQoL paradox,” affirming that the questionnaire captures distinct patient-centered outcomes not redundant with pure physiological testing.
• Stronger correlations are observed with functional exercise capacity, such as the Six-Minute Walk Distance (6MWD; r = -.48 to -.58), underscoring that the instrument’s limitation domain directly reflects tangible functional exercise tolerance.

Discriminant and Known-Groups Validity

The instrument reliably discriminates between patient cohorts stratified by clinical severity. Statistically significant gradient differences in RIQ-MON10 scores have been established across:

• GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I through IV, with mean scores deteriorating progressively alongside advancing GOLD classification (p < .001).
• Exacerbation frequency: Patients experiencing frequent exacerbations (≥ 2 exacerbations per annum) exhibit markedly higher scores (indicating worse quality of life) than non-frequent exacerbators.
• Smoking status and oxygen dependency: Patients requiring continuous supplemental ambulatory oxygen display significantly higher limitation scores relative to non-oxygen-dependent peers.

8. Reliability

Extensive psychometric testing supports the operational reliability of the RIQ-MON10 across diverse clinical strata and language adaptations.

Internal Consistency

Despite the substantial item reduction from the original 55-item inventory down to 10 items, the scale preserves high internal consistency without exhibiting redundant item collinearity. Across empirical studies in adult and elderly COPD and asthma cohorts:

• Physical and Emotional Complaints Subscale (5 items): Cronbach’s alpha values range from α = .78 to .84.
• Physical and Social Limitations Subscale (5 items): Cronbach’s alpha values range from α = .81 to .87.
• Total RIQ-MON10 Scale (10 items): Cronbach’s alpha coefficients consistently range between α = .84 and .89.

These values satisfy the classical psychometric criteria established by Nunnally and Bernstein (.70 for group-level research, .80 to .90 for clinical monitoring), confirming that the instrument achieves high measurement precision despite its brevity.

Test-Retest Reliability and Measurement Stability

The stability of the RIQ-MON10 has been assessed in clinically stable outpatients over testing intervals ranging from 1 to 4 weeks:

• The intraclass correlation coefficients (ICC) for the overall score consistently exceed .82, with subscale ICCs ranging from .79 to .86.
• The standard error of measurement (SEM) has been established at approximately 0.35 to 0.42 on a 7-point scale, demonstrating minimal random measurement error under stable physiological conditions.

Responsiveness to Clinical Change

A critical attribute for a longitudinal monitoring instrument is longitudinal sensitivity to clinically meaningful interventions. The RIQ-MON10 demonstrates moderate-to-large effect sizes (Cohen’s d ranging from 0.50 to 0.78; standardized response mean [SRM] > 0.60) following 8- to 12-week comprehensive pulmonary rehabilitation programs and following recovery from acute inpatient COPD exacerbations.

9. Factor Analysis

The structural dimensionality of the RIQ-MON10 has been scrutinized utilizing both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).

Exploratory Factor Analysis (EFA)

During the original derivation phase from the 55-item QoL-RIQ, principal component analysis with oblique (Oblimin) rotation revealed that the heterogeneous multi-domain structure of the parent instrument (which comprised separate subscales for breathing problems, physical activities, emotions, general activities, daily and social activities, and sexuality) coalesced into two dominant, orthogonal-to-oblique latent dimensions when selecting items with the highest discriminatory power and clinical monitoring sensitivity:

• Factor 1: Physical and Emotional Complaints — Characterized by strong primary factor loadings (.62 to .85) for items addressing acute dyspnea sensations, cough-related exhaustion, nocturnal awakening, anxiety regarding breathing, and feelings of vulnerability. Cross-loadings onto Factor 2 are systematically below .25.
• Factor 2: Physical and Social Limitations — Characterized by substantial primary loadings (.58 to .82) for items measuring walking impairment, stair climbing, household chores, disruption of leisure pursuits, and curtailment of social interactions. Cross-loadings onto Factor 1 remain consistently below .20.

Confirmatory Factor Analysis (CFA)

Subsequent confirmatory investigations evaluating the two-factor oblique model have verified its statistical fit across diverse cohorts of pulmonary patients. In baseline validation samples, structural equation models specifying two correlated latent factors have repeatedly demonstrated superior fit compared to single-factor unidimensional models. Exemplary model fit indices reported in structural validation studies include:

• Comparative Fit Index (CFI): .94 to .97 (surpassing the standard ≥ .90 threshold for acceptable fit).
• Tucker-Lewis Index (TLI): .93 to .96.
• Root Mean Square Error of Approximation (RMSEA): .048 to .065 (90% CI: [.035, .078]), indicating adequate-to-close approximate model fit.
• Standardized Root Mean Square Residual (SRMR): .039 to .051.

The correlation between the two latent factors typically ranges between r = .52 and .68. This moderate-to-high inter-factor correlation confirms that while physical complaints and daily functional limitations are inextricably linked within the overall experience of chronic respiratory illness, they remain psychometrically distinct constructs that warrant differentiated scoring and reporting in clinical decision-making.

10. Instrument / Measurement Tool

• Instrument Name: Respiratory Illness Questionnaire-Monitoring 10 (RIQ-MON10 / Riq-mon10).
• Parent Scale: Quality of Life for Respiratory Illness Questionnaire (QoL-RIQ; 55 items; Maille et al., 1994, 1997).
• Test Classification: Patient-Reported Outcome Measure (PROM); disease-specific health-related quality of life (HRQoL) monitoring tool.
• Administration Format: Self-administered pencil-and-paper survey, electronic PROM (ePROM), clinician-assisted interview, or digital tablet/web application.
• Target Population: Adult and elderly individuals (aged 18 years and older) diagnosed with chronic respiratory conditions, primarily Chronic Obstructive Pulmonary Disease (COPD, GOLD Stages I–IV) and chronic bronchial asthma.
• Number of Items: 10 items.
• Recall Period: Standardized recall of the preceding 1 to 2 weeks of clinical status.
• Scale Structure & Subscales:
  • Subscale 1: Physical and Emotional Complaints (5 items measuring acute dyspnea, fatigue, respiratory symptoms, and affective distress/anxiety).
  • Subscale 2: Physical and Social Limitations (5 items measuring functional mobility, household activities, social engagement, and leisure curtailment).
• Response Scale: Typically presented as a 7-point Likert-type scale (ranging from 1 = “Not at all / Never” to 7 = “Extremely / Constantly” or equivalent frequency/severity anchors adapted from the parent QoL-RIQ).
• Scoring Algorithm:
  • Subscale Scores: Computed by calculating the arithmetic mean of completed items within each 5-item domain (yielding a range of 1.0 to 7.0 per subscale).
  • Overall Score: Calculated as the unweighted mean of all 10 items (ranging from 1.0 to 7.0), where higher numerical values indicate greater symptom burden and more severe functional impairment (poorer quality of life).
  • Missing Data Rule: If more than one item is missing within a given 5-item subscale, that subscale score cannot be validly computed; if single items are missing, mean imputation from completed domain items is standard practice.
• Completion Time: Approximately 2 to 4 minutes.

11. Permissions & Fee and Test Year

The Respiratory Illness Questionnaire-Monitoring 10 was developed and published in 1997 by Dr. Albert R. Maille and colleagues as part of academic research initiatives in primary care respiratory medicine at Leiden University Medical Center (LUMC) and the Netherlands Institute for Health Services Research (NIVEL).

The copyright and intellectual property rights associated with the RIQ-MON10 and its parent instrument (QoL-RIQ) reside with the original developer and affiliated academic research consortia. Generally, the instrument is made available free of charge for non-commercial academic research, public healthcare initiatives, pulmonary rehabilitation monitoring, and routine clinical care upon proper attribution. However, for use within commercially sponsored pharmaceutical clinical trials, proprietary electronic health record integrations, or commercial software applications, explicit licensing, user agreements, and written permission must be obtained from the copyright holders or representative distribution bodies. Clinicians and researchers wishing to utilize the official validated Dutch or English forms should contact the developer or consult the original institutional repositories at Leiden University Medical Center or NIVEL.

12. References

• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992). A self-complete measure of health status for chronic airflow limitation: The St. George’s Respiratory Questionnaire. American Review of Respiratory Disease, 145(6), 1321–1327. https://doi.org/10.1164/ajrccm/145.6.1321
• Kaptein, A. A., Brand, P. L., Dekker, F. W., Kerstjens, H. A., Postma, D. S., & Sluiter, H. J. (1993). Quality-of-life evaluation in asthma and chronic obstructive pulmonary disease. European Respiratory Review, 3(12), 402–407.
• Maille, A. R. (1997). The Quality of Life for Respiratory Illness Questionnaire (QoL-RIQ): Development, psychometric properties, and clinical applications of a disease-specific instrument for patients with asthma and COPD (Doctoral dissertation). Leiden University, Leiden, The Netherlands.
• Maille, A. R., Kaptein, A. A., Koning, C. J., & Zwinderman, A. H. (1994). Developing a quality of life questionnaire for respiratory illness (QoL-RIQ): A disease-specific measure for patients with asthma and chronic obstructive pulmonary disease. Quality of Life Research, 3(1), 47–48.
• Maille, A. R., Koning, C. J., Zwinderman, A. H., Willems, L. N., Dijkman, J. H., & Kaptein, A. A. (1996). The development of the quality-of-life for respiratory illness questionnaire (QoL-RIQ): A disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Quality of Life Research, 5(3), 301–311. https://doi.org/10.1007/BF00433915
• Maille, A. R., Kaptein, A. A., de Haes, J. C., & Everaerd, W. (1997). Assessing health-related quality of life in chronic respiratory patients: A review of disease-specific instruments. Respiratory Medicine, 91(8), 453–466. https://doi.org/10.1016/S0954-6111(97)90069-4
• van der Molen, T., Willemse, B. W., Schokker, S., Ten Hacken, N. H., Postma, D. S., & Juniper, E. F. (2003). Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and Quality of Life Outcomes, 1, Article 13. https://doi.org/10.1186/1477-7525-1-13
• Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. https://doi.org/10.1097/00005650-199206000-00002
• World Health Organization. (2001). International Classification of Functioning, Disability and Health: ICF. World Health Organization.

13. Items of the Scale